ATAI News and Press, ATAI Life Sciences N.V. From 12/28/22

Every few years, new or previously forgotten discoveries shake up the very foundation of how industries operate. The development of the internet, for instance, altered society in a multitude of ways, enabling previously unknown ways of connecting and thinking and completely revolutionizing how ...

-   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 -   KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models -   An as...

The landscape for success with psychedelics companies is still shaping up, with more companies getting into the space or developing partnerships to help them grow faster and do more with their resources. The year 2022 has been a story of shifting personnel, big buyouts and collaborations, new...

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-ye...

NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massa...

Summary Welcome to the first ever Psychedelic Sunday episode! There is a lot of overlap between the cannabinoid and psychedelic experiences and today we launch our coverage of the psychedelics industry. Challenges and opportunities within psychedelics. Highlighting 4 stocks: Com...

Interest in psychedelic-assisted therapies has blown up over the past couple of years amid surging interest in psychedelic medications across the mainstream and scientific communities. As America’s mental health crisis has grown, there has been increased interest in alternative treatme...

If you have been paying attention to the internet and the mainstream media for the past couple of years, you probably noticed that psychedelics are all the rage these days. Even though psychedelics are rigidly controlled at the federal level, initial research indicates that they have the potent...

- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - ...

The current wave of surging psychedelic research and mainstream popularity has been dubbed the psychedelic renaissance. Decades after they were prohibited, hallucinogenic drugs are revealing astonishing mental-health benefits in clinical trials. Research has shown that even a single dose...